Masimo Corp. ((MASI)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Masimo Corp. is conducting a study titled ‘Investigation of Skin Pigmentation Effect on Performance of Masimo Pulse Oximetry (INSPIRE).’ The study aims to evaluate how skin pigmentation affects the performance of Masimo RD SET® SpO2 sensors, particularly in patients with hypoxemia in intensive care settings. This research is significant as it seeks to ensure the accuracy of pulse oximetry across diverse skin tones, which is crucial for patient safety and care.
The intervention being tested is the RD SET Sensor, a device used to measure blood oxygen levels. This sensor is being evaluated for its performance across different skin pigmentation levels to ensure consistent and reliable readings.
The study follows an interventional design with a sequential intervention model. There is no allocation or masking involved, and the primary purpose is categorized as ‘other,’ focusing on evaluating device performance rather than therapeutic outcomes.
The study began on February 23, 2024, with a primary completion date yet to be announced. The most recent update was submitted on July 31, 2025. These dates are important as they indicate the study’s progress and potential timeline for results, which can influence investor decisions.
This study update could impact Masimo’s stock performance by potentially enhancing investor confidence if the results demonstrate improved device accuracy. It also positions Masimo competitively within the medical device industry, especially if the study addresses a known gap in pulse oximetry performance across different skin tones.
The study is ongoing, with further details available on the ClinicalTrials portal.